Mike Mathias Joins Endologix as Chief Commercial Officer

Endologix LLC has appointed Mike Mathias as chief commercial officer.  
 
“We are delighted to bring such an experienced and successful leader into Endologix. Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans,” Endologix President/CEO Matt Thompson, M.D., said. “His extensive experience and success in launching therapies in the medical device industry make him an invaluable asset to our senior leadership team. We believe that with Mike’s leadership, our global sales, business development, and marketing teams will continue to thrive.”
 
With more than three decades of leadership in commercial organizations within the medical device industry, Mathias has contributed to the advancement of endovascular aneurysm repair (EVAR) and therapies for peripheral vascular disease. His tenure included pivotal roles, notably leading the U.S. launch of the LimFlow System. Prior to joining LimFlow Inc, he spent 20 years in various commercial leadership roles at Medtronic. He led Medtronic’s $1.2 billion Heart Valve Therapies U.S commercial operations, launching Transcatheter Aortic Valve Replacement (TAVR). Mathias’s tenure at both Medtronic and LimFlow is distinguished by the launch of therapies, demonstrating his strategic planning, team leadership, and capability for market expansion.

Mathias earned his bachelor of science degree in Arabic and French Studies from the U.S. Military Academy at West Point, and an MBA from the University of Minnesota.

“Joining Endologix at such a critical juncture is an honor. I am excited to apply my experience to innovate and join the leadership team,” Mathias stated. “Together, we will work to enhance our commercial strategy, ensuring success for our commercial teams and the organization as a whole.”
 
Endologix LLC develops therapies for interventional vascular disease treatment. Endologix’s therapeutic portfolio includes a variety of products in various stages of development designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, Calif.